A Phase 2 trial of AR301 in walnut allergy
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2018
Price : $35 *
At a glance
- Drugs Tosatoxumab (Primary)
- Indications Food hypersensitivity
- Focus Therapeutic Use
- 08 Aug 2018 According to an Aimmune Therapeutics media release, the company Submit Investigational New Drug Application for AR301 in walnut allergy in 2H of 2019.
- 16 Mar 2018 New trial record
- 12 Mar 2018 According to an Aimmune Therapeutics media release, the company is planning to start this trial in 2H 2019.